[A22-46] Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V
Last updated 09.09.2022
Project no.:
A22-46
Commission:
Commission awarded on 19.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Children's and adolescents' health
Children between 6 and 11 years of age with severe asthma with type 2 inflammation which is not properly controlled despite moderate-to-high-dose inhaled corticosteroids (ICS) plus one further drug as maintenance treatment.
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on Jul 15, 2022.
Accompanying information